Teva's AUSTEDO Shows Real-World Quality-of-Life Gains in Huntington's Disease
Event summary
- Teva presented real-world data showing 60-71% of Huntington's disease patients reported quality-of-life improvements after AUSTEDO/AUSTEDO XR treatment.
- 83% of caregivers noted reduced daily life impact due to patients' improved chorea management.
- Study was the first decentralized, real-world assessment of deutetrabenazine's impact on HD chorea.
- Data presented at the Advanced Therapeutics in Movement & Related Disorders® Congress (June 4-8, 2026).
The big picture
Teva's findings highlight the growing importance of patient-reported outcomes in neurodegenerative disease treatment. The data positions AUSTEDO as a potential standard in HD chorea management, where effective symptom control can significantly improve both patient independence and caregiver quality of life. This comes as Teva continues its strategic shift toward becoming a leading innovative biopharmaceutical company.
What we're watching
- Market Differentiation
- Whether Teva can leverage these real-world outcomes to strengthen AUSTEDO's market position against competitors in HD chorea treatment.
- Regulatory Strategy
- How Teva will use this data to potentially expand indications or support pricing discussions with payers.
- Pipeline Leverage
- The pace at which Teva can translate this success into broader neuroscience portfolio growth.
Related topics